ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
68.294,54
0,84%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cymabay Therapeutics Inc (CBAY)

  7. Cymabay Therapeutics Inc (CBAY) News

CBAY

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CBAY
DatumZeitQuelleÜberschriftSymbolFirma
22/03/202414h18Business WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:CBAYCymabay Therapeutics Inc
11/03/202414h14Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
07/03/202422h35Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
28/02/202423h01Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
23/02/202412h25Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:CBAYCymabay Therapeutics Inc
16/02/202423h14Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CBAYCymabay Therapeutics Inc
15/02/202422h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
15/02/202400h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
14/02/202422h46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
14/02/202418h50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CBAYCymabay Therapeutics Inc
14/02/202415h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
13/02/202422h27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CBAYCymabay Therapeutics Inc
12/02/202423h29Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CBAYCymabay Therapeutics Inc
12/02/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
12/02/202419h43PR Newswire (US)Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmNASDAQ:CBAYCymabay Therapeutics Inc
12/02/202414h45Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CBAYCymabay Therapeutics Inc
12/02/202414h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CBAYCymabay Therapeutics Inc
06/02/202423h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
01/02/202423h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
31/01/202400h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
29/01/202423h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
27/01/202400h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CBAYCymabay Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CBAY

Kürzlich von Ihnen besucht

TG
MBG
MercedesBenz
NASDAQ
AAPL
Apple
TG
TUI1
Tui
TG
BAYN
Bayer
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
TG
CBK
Commerzbank
NASDAQ
TSLA
Tesla
TG
D7G
Nel ASA
AMEX
XLV
Health Care Select Sector
AMEX
SPY
SPDR S&P 500
TG
NOV
Novo Nordisk
TG
ALV
Allianz
FX
EURGBP
Euro vs Sterling
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten